fig2
![Opportunities and challenges in developing tissue-agnostic anti-cancer drugs](https://image.oaes.cc/d4741149-2b17-4a90-a745-614ac654abaf/3477.fig.2.jpg)
Figure 2. Oncogenic fusions lead to ligand-independent, constitutive activation of kinases and their downstream signal pathways. A: Fusions with N-terminal partners, represented by tropomyosin receptor kinase (TRK) fusions; B: fusions with C-terminal partners, represented by fibroblast growth factor receptor fusions. AKT: protein kinase B